FDA adverse-event reporting forms cut the Gender field and keep only Male/Female "Sex"

90 FR 27029. OMB-submission notice for FDA's Adverse Event and Product Experience Reporting Program. In Section A and Section E of the forms, FDA proposes, based on EO 14168, to revise the Sex field to two options, Male and Female, and remove the Gender field. The edit repeats across the voluntary and mandatory reporting form revisions. Related to catalogue S11-020/S20-125 (FDA proposal to purge "gender" from Title 21) but a separate action.